Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel RT-PCR Test Enables Early Detection of Parkinson’s Disease

By LabMedica International staff writers
Posted on 29 Sep 2023

Parkinson's disease (PD) is a neurological disorder with no known definitive cause, although it is thought that both genetics and environmental factors play a role. More...

There is currently no cure for the disease. When patients begin to show typical signs of PD, a significant loss of dopamine-producing cells has already occurred, making it difficult to halt further brain decline. As the disease advances, problems with movement and speech arise, affecting the individual's independence. For these reasons, genetic testing becomes vital for assessing an individual's risk and for early detection. Identifying specific genetic mutations linked to PD not only helps people make educated healthcare choices but also guides researchers in developing targeted treatments. Understanding these genetic factors can further contribute to personalized treatment strategies, improving patient care.

In the search for early detection methods for PD, accurately identifying the condition has proven to be challenging. Anbio Biotechnology (Frankfurt, Germany) has developed a promising approach using real-time polymerase chain reaction (RT-PCR) technology for early PD detection. Studies have found that early-onset PD is commonly associated with mutations in the GBA and LRRK2 genes. Among these mutations, L444P, G2385R, and R1628P are notably prevalent. To address this, Anbio has introduced its GBA L444P/LRRK2 R1628P/LRRK2 G2385R Gene Mutations Polymorphism Test Kit. This RT-PCR assay is specifically designed to rapidly and accurately identify these three key genetic polymorphisms in the GBA and LRRK2 genes.

The kit employs a highly specialized Taq enzyme and fluorescent probes to enhance detection specificity. Quality control is maintained through the use of internal and multiple positive controls, reducing the chances of false negatives and positives. The test can identify these three specific GBA and LRRK2 genetic polymorphisms in as little as 117 minutes. The procedure is straightforward, and the test results are easy to understand, objective, and reliable. When it comes to accuracy, sensitivity, and specificity, the kit outperforms other similar products available on the market. The findings generated by Anbio's test kit are significant not only for understanding the mechanisms behind PD but also for shaping effective treatment strategies.

Related Links:
Anbio Biotechnology 


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
Gold Member
Auto Hematology Analyzer
DH-88CS [H]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.